Cantor Fitzgerald Issues Positive Estimate for FATE Earnings

Fate Therapeutics, Inc. (NASDAQ:FATE) – Stock analysts at Cantor Fitzgerald upped their FY2025 earnings per share estimates for Fate Therapeutics in a report issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now expects that the biopharmaceutical company will earn ($1.20) per share for the year, up from their previous estimate of ($1.67). The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share.

Other research analysts have also issued reports about the stock. Needham & Company LLC reiterated a “hold” rating on shares of Fate Therapeutics in a research note on Thursday, March 6th. Wells Fargo & Company reduced their price target on Fate Therapeutics from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday, March 6th. StockNews.com cut Fate Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 11th. Wedbush reaffirmed a “neutral” rating and set a $5.00 target price on shares of Fate Therapeutics in a report on Thursday, March 6th. Finally, Stifel Nicolaus decreased their price target on Fate Therapeutics from $5.00 to $3.00 and set a “hold” rating on the stock in a research report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $5.50.

Fate Therapeutics Stock Up 3.4 %

NASDAQ FATE opened at $0.94 on Thursday. The firm has a market cap of $107.34 million, a P/E ratio of -0.57 and a beta of 2.26. The company’s 50 day moving average is $1.22 and its 200-day moving average is $2.20. Fate Therapeutics has a 12-month low of $0.87 and a 12-month high of $7.70.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings data on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.13. The business had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $1.57 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%.

Institutional Trading of Fate Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of FATE. Vestal Point Capital LP increased its position in shares of Fate Therapeutics by 46.3% in the fourth quarter. Vestal Point Capital LP now owns 2,465,000 shares of the biopharmaceutical company’s stock worth $4,067,000 after purchasing an additional 780,000 shares during the last quarter. Squarepoint Ops LLC grew its stake in Fate Therapeutics by 154.2% in the 4th quarter. Squarepoint Ops LLC now owns 34,295 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 20,805 shares in the last quarter. Tang Capital Management LLC increased its holdings in shares of Fate Therapeutics by 165.1% in the 4th quarter. Tang Capital Management LLC now owns 1,855,954 shares of the biopharmaceutical company’s stock worth $3,062,000 after buying an additional 1,155,954 shares during the last quarter. Sphera Funds Management LTD. purchased a new stake in shares of Fate Therapeutics during the 4th quarter valued at $655,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Fate Therapeutics during the 4th quarter worth $55,000. Hedge funds and other institutional investors own 97.54% of the company’s stock.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.